216 A UK survey on the assessment and management of CF-associated liver disease  by Honeybourne, D. et al.
S112 9. Gastrointestinal/Liver Disease/Metabolic Complications of CF/Nutrition Posters
216 A UK survey on the assessment and management of
CF-associated liver disease
D. Honeybourne1, E.F. Nash1, P.N. Newsome2, J.L. Whitehouse1. 1Heartlands
Hospital, West Midlands Adult CF Centre, Birmingham, United Kingdom;
2University Hospital Birmingham, Liver Unit, Birmingham, United Kingdom
This survey was designed to assess the amount of variation around the UK in the
investigation and management of CF related liver disease (CFLRD). Questionnaires
were devised by a group of adult and paediatric CF physicians and also hepatologists
and were sent to all major CF centres in the UK. 16 adult and 24 paediatric centres
replied. The number of new CFLD cases ranged from 0−5 per year per centre. No
centre carried out routine diagnostic liver biopsy and most centres did not use a
severity scoring system. Non-invasive imaging other than ultrasound was mentioned
by only 5 centres. In established CFLD, all centres monitored platelets, prothrombin
time and albumin. Ultrasound monitoring varied between 6 monthly, annually or
ad hoc. There was wide variation in screening for varices. Only 16 centres ran
a joint clinic with a hepatologist but 38 centres had access to a hepatologist
with a special interest in CFLD. Nearly all centres used lifelong URSO treatment
for patients with, doses of 10−30mg/kg/day but only 5 centres used taurine. All
adult centres advocated primary prophylaxis for grade 2+ varices and the majority
preferred banding to beta blockade. Most centres considered triggers for referral
for liver transplant to be one or more of: ascites, bleeding varices and impaired
synthetic function but there was less consensus on proximal muscle wasting. 15
out of 40 centres felt that they did not have an adequate forum to discuss liver
transplant issues. In summary, our survey showed wide variation in the assessment
and management of CFLD in the UK with some differences compared to recent
European guidance [1].
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Objectives: While pulmonary disease remains the main cause of morbidity and
mortality in cystic ﬁbrosis patients, Cystic Fibrosis Liver Disease is assuming
increased importance as patients with CF live longer. Early identiﬁcation is difﬁcult
to diagnose clinically or biochemically. We aim to assess effectiveness of liver
ultrasound in CF patients in identifying progression from normal scan towards
CFLD.
Methods: Retrospective review of sequential liver ultrasounds over 10 years were
used to identify trends in CFLD progression. Comparisons of serial liver scans
in individual patients were quantiﬁed based on radiological reports from a tertiary
children’s hospital. Radiological reports were graded on basis of progression towards
liver disease.
Conclusions: 101 CF patients were identiﬁed over ten years. 59 were male. 27 were
excluded for having undergone one or less scans. 401 scans were reviewed in total;
94 [23%] were abnormal. 54 [13%] scans in 29 patients showed fatty inﬁltration.
18 [4%] scans in 10 patients demonstrated increased echogenicity with non-speciﬁc
changes. 22 [5%] studies in 6 patients had liver cirrhosis. Liver disease progression
was assessed by comparison of subsequent scans in individual patients. 258 [81%]
of 320 comparisons showed no change. 29 [9%] scans subsequently showed
progression of disease. Interestingly, 33 [10%] showed reversion towards normality.
It is unclear whether this is related to interoperator variability, a characteristic of
CFLD, or due to a combination of both.
While independently, ultrasound has diagnostic limitations, it remains a useful tool
in identifying early and late CFLD when used in conjunction with clinical exam.
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Cystic ﬁbrosis liver disease (CFLD) is the second cause of death in cystic ﬁbrosis
(CF) after pulmonary disease, with an increasing prevalence. The main pathogenic
lesion of cirrhosis is liver ﬁbrosis who‘s early detection could predict the following
outcome. Elastography seems to be a useful tool in liver ﬁbrosis assessment.
Objectives: Evaluate the utility of the transient elastography in addition to ultra-
sound for CFLD early diagnosis and monitoring in our CF patients.
Methods: Fifty-one patients with CFLD were followed for 2 years. Adjacent to
biochemical and biannual examination, transient elastography was performed in
conjuction with ultrasound evaluation. Williams ultrasound scoring system was used
for grading the liver alterations in stage 1 − mild (points <3), stage 2 − moderate
(4−8 points), stage 3 − severe (>8−9 points). Control group age matched included
36 healthy children.
Results: Outcomes at baseline showed that most of patients 62.74% (32 patients)
had moderate stage 2 liver disease, with median value liver stiffness 8.8 kPa. Only
9.8% (5 patients) had liver cirrhosis, with ultrasound score >9 and median elasticity
14.6 kPa. 14 patients (27.4%) had CFLD stage 1, ultrasound features consisting in
hyperechogenity and mean elasticity was increase 7.6 kPa compared to controls,
suggesting ﬁbrosis in cases considered as liver steatosis. Median ﬁbrosis score in
children with CFLD was 10.33 kPa compared to controls.
Conclusion: Elastography is a valuable method for evaluation of liver ﬁbrosis in
CF patients, helping with differentiation between steatosis and ﬁbrosis. Early CFLD
diagnosis with consequent intervention could prolong CF children’s life.
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Introduction: Cystic ﬁbrosis related liver disease (CFRLD) reported incidence is
between 27% and 35%. A spectrum of hepatobiliary disease can occur in cystic
ﬁbrosis (CF), with a small number progressing to liver failure. Liver cirrhosis is
the largest non-pulmonary cause of death occurring in approximately 2.5% of CF
mortality.
Objective: To assess the prevalence of CFRLD in the N. Ireland adult CF
population.
Methods: A retrospective review of case records of the CF adult population
was undertaken. Age, FEV1, BMI, microbiology status, USS and OGD results,
documented gastrointestinal and hepatic disease were recorded. Evidence of referral
to a gastroenterologist/hepatologist and liver transplant status were also recorded.
Results: 241 patients were identiﬁed (135M/106F). Mean (SD) age 31(11.5),
FEV1% 71.4(22.4), BMI 23(3.6) kg/m2. 45% were infected with P. aeruginosa,
9% BCC and 38% non-Pseudomonas. The commonest reported genetic mutations
were 34% F508/F508, 10% F508/R117H, 5% F508/G551D and 25% F508/other.
85% had an USS, with splenomegaly present in 10%, fatty liver in 16% cirrhosis in
4%. 11% had evidence of biliary disease and 8% had a ﬁnal diagnosis of CFRLD.
In the CFRLD group 60% were F508/F508. CFRLD is more common in F508
homozygotes (p = 0.01). One death from liver disease occurred and one is transplant
listed.
Conclusion: This is a lower than expected prevalence of liver disease in comparison
with data from Nash et al 2008 (cirrhosis in 28%, fatty liver in 3% and splenomegaly
in 6%). This may be due to inaccurate coding or potential genetic differences seen
in N. Ireland. F508 homozygotes appear to have a higher incidence of CFRLD than
other mutations.
